Get started
Editas Medicine, Inc.Editas Medicine, Inc.Editas Medicine, Inc.

Editas Medicine, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsETFs

Live chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪295.08 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.263 CHF
Net income (FY)
‪−215.33 M‬ CHF
Revenue (FY)
‪29.35 M‬ CHF
Shares float
‪89.11 M‬
Beta (1Y)
2.43

Employees


Employees (FY)
246
Change (1Y)
−19 −7.17%
Revenue / Employee (1Y)
‪119.30 K‬ CHF
Net income / Employee (1Y)
‪−875.32 K‬ CHF

About Editas Medicine, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Gilmore O’Neill
Website
editasmedicine.com
Headquarters
Cambridge
Founded
2013
ISIN
US28106W1036
FIGI
BBG00LVD8LB3
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as 8EM.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs


SELJLB
Selectra Investments SICAV - J. Lamarck Biotech
Weight
4.31%
Market value
‪3.83 M‬
USD
IWN
iShares Russell 2000 Value ETF
Weight
0.02%
Market value
‪2.78 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.03%
Market value
‪2.07 M‬
USD
DFAT
Dimensional U.S. Targeted Value ETF
Weight
0.01%
Market value
‪1.43 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.00%
Market value
‪838.05 K‬
USD
IWC
iShares Micro-Cap ETF
Weight
0.07%
Market value
‪769.33 K‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.03%
Market value
‪249.75 K‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.03%
Market value
‪249.75 K‬
USD
NXTE
AXS Green Alpha ETF
Weight
0.53%
Market value
‪240.82 K‬
USD
VTWV
Vanguard Russell 2000 Value ETF
Weight
0.02%
Market value
‪188.37 K‬
USD
WDNA
WisdomTree BioRevolution UCITS ETF AccumUSD
Weight
1.39%
Market value
‪130.41 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 8EM is 3.345 CHF — it has increased by 193.94% in the past 24 hours. Watch Editas Medicine, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Editas Medicine, Inc. stocks are traded under the ticker 8EM.
We've gathered analysts' opinions on Editas Medicine, Inc. future price: according to them, 8EM price has a max estimate of 4.81 CHF and a min estimate of 0.80 CHF. Watch 8EM chart and read a more detailed Editas Medicine, Inc. stock forecast: see what analysts think of Editas Medicine, Inc. and suggest that you do with its stocks.
8EM reached its all-time high on Sep 16, 2021 with the price of 56.187 CHF, and its all-time low was 1.138 CHF and was reached on Jan 15, 2025. View more price dynamics on 8EM chart.
See other stocks reaching their highest and lowest prices.
8EM stock is 65.98% volatile and has beta coefficient of 2.43. Track Editas Medicine, Inc. stock price on the chart and check out the list of the most volatile stocks — is Editas Medicine, Inc. there?
Today Editas Medicine, Inc. has the market capitalization of ‪277.76 M‬, it has increased by 7.25% over the last week.
Yes, you can track Editas Medicine, Inc. financials in yearly and quarterly reports right on TradingView.
Editas Medicine, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
8EM earnings for the last quarter are −0.50 CHF per share, whereas the estimation was −0.31 CHF resulting in a −61.31% surprise. The estimated earnings for the next quarter are −0.24 CHF per share. See more details about Editas Medicine, Inc. earnings.
Editas Medicine, Inc. revenue for the last quarter amounts to ‪2.84 M‬ CHF, despite the estimated figure of ‪1.83 M‬ CHF. In the next quarter, revenue is expected to reach ‪3.94 M‬ CHF.
8EM net income for the last quarter is ‪−42.24 M‬ CHF, while the quarter before that showed ‪−67.36 M‬ CHF of net income which accounts for 37.29% change. Track more Editas Medicine, Inc. financial stats to get the full picture.
No, 8EM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 22, 2025, the company has 246 employees. See our rating of the largest employees — is Editas Medicine, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Editas Medicine, Inc. EBITDA is ‪−122.24 M‬ CHF, and current EBITDA margin is −721.39%. See more stats in Editas Medicine, Inc. financial statements.
Like other stocks, 8EM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Editas Medicine, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Editas Medicine, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Editas Medicine, Inc. stock shows the buy signal. See more of Editas Medicine, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.